Should the offer be accepted, Natco Pharma will hold a 35.75% stake in Adcock Ingram, valued at ₹400 crore. Previous Post Sapphire Foods Q1 Results: Stock ends higher despite net loss, margin contraction Next Post Syngene Q1 Results: Numbers better than analyst expectations, FY26 guidance maintained Leave a ReplyCancel ReplyYour email address will not be published. Required fields are marked * Name * Email * Website Add Comment * Save my name, email, and website in this browser for the next time I comment.Post Comment
